ES2337252T3 - Suspensiones liquidas farmaceuticas. - Google Patents

Suspensiones liquidas farmaceuticas. Download PDF

Info

Publication number: ES2337252T3
Authority: ES; Spain
Prior art keywords: particles; pfc; stable; liquid; suspended
Prior art date: 2000-10-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES04013422T

Other languages

English (en)

Spanish (es)

Inventor

Bruce Joseph Roser

Arcadio Garcia De Castro

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

NOVA BIO PHARMA TECHNOLOGIES L

NOVA BIO-PHARMA TECHNOLOGIES Ltd

Original Assignee

NOVA BIO PHARMA TECHNOLOGIES L

NOVA BIO-PHARMA TECHNOLOGIES Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-13

Filing date

2000-10-13

Publication date

2010-04-22

2000-10-13 Application filed by NOVA BIO PHARMA TECHNOLOGIES L, NOVA BIO-PHARMA TECHNOLOGIES Ltd filed Critical NOVA BIO PHARMA TECHNOLOGIES L

2010-04-22 Application granted granted Critical

2010-04-22 Publication of ES2337252T3 publication Critical patent/ES2337252T3/es

2020-10-13 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000006194 liquid suspension Substances 0.000 title 1
239000002245 particle Substances 0.000 claims abstract description 95
239000000725 suspension Substances 0.000 claims abstract description 48
239000007788 liquid Substances 0.000 claims abstract description 37
239000013078 crystal Substances 0.000 claims abstract description 36
235000000346 sugar Nutrition 0.000 claims abstract description 28
TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims abstract description 5
239000004480 active ingredient Substances 0.000 claims abstract description 3
239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
239000000203 mixture Substances 0.000 claims description 27
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical group [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 12
239000001506 calcium phosphate Substances 0.000 claims description 9
229910000389 calcium phosphate Inorganic materials 0.000 claims description 9
235000011010 calcium phosphates Nutrition 0.000 claims description 9
239000003795 chemical substances by application Substances 0.000 claims description 5
MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 4
239000001527 calcium lactate Substances 0.000 claims description 4
229960002401 calcium lactate Drugs 0.000 claims description 4
235000011086 calcium lactate Nutrition 0.000 claims description 4
230000001105 regulatory effect Effects 0.000 claims description 2
229910017053 inorganic salt Inorganic materials 0.000 claims 2
239000000843 powder Substances 0.000 description 34
229960005486 vaccine Drugs 0.000 description 32
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
239000003921 oil Substances 0.000 description 23
238000009472 formulation Methods 0.000 description 18
239000003814 drug Substances 0.000 description 16
238000001035 drying Methods 0.000 description 15
238000002360 preparation method Methods 0.000 description 15
239000013543 active substance Substances 0.000 description 14
229940079593 drug Drugs 0.000 description 14
239000012071 phase Substances 0.000 description 14
239000000243 solution Substances 0.000 description 13
239000000126 substance Substances 0.000 description 10
239000004094 surface-active agent Substances 0.000 description 10
229950011087 perflunafene Drugs 0.000 description 9
UWEYRJFJVCLAGH-IJWZVTFUSA-N perfluorodecalin Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)[C@@]2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)[C@@]21F UWEYRJFJVCLAGH-IJWZVTFUSA-N 0.000 description 9
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 8
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 8
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 8
238000000889 atomisation Methods 0.000 description 8
238000002347 injection Methods 0.000 description 8
239000007924 injection Substances 0.000 description 8
238000000034 method Methods 0.000 description 8
239000000047 product Substances 0.000 description 8
239000002671 adjuvant Substances 0.000 description 7
239000011521 glass Substances 0.000 description 7
238000002649 immunization Methods 0.000 description 7
230000003053 immunization Effects 0.000 description 7
239000000463 material Substances 0.000 description 7
239000004005 microsphere Substances 0.000 description 7
QKENRHXGDUPTEM-UHFFFAOYSA-N perfluorophenanthrene Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C3(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C3(F)C(F)(F)C(F)(F)C21F QKENRHXGDUPTEM-UHFFFAOYSA-N 0.000 description 7
239000007787 solid Substances 0.000 description 7
239000003981 vehicle Substances 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 6
230000000694 effects Effects 0.000 description 6
230000002209 hydrophobic effect Effects 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
150000008163 sugars Chemical class 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
239000000872 buffer Substances 0.000 description 5
239000012530 fluid Substances 0.000 description 5
238000005057 refrigeration Methods 0.000 description 5
239000002904 solvent Substances 0.000 description 5
238000003860 storage Methods 0.000 description 5
102000002260 Alkaline Phosphatase Human genes 0.000 description 4
108020004774 Alkaline Phosphatase Proteins 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
229930195725 Mannitol Natural products 0.000 description 4
230000002776 aggregation Effects 0.000 description 4
238000004220 aggregation Methods 0.000 description 4
239000000084 colloidal system Substances 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
230000002255 enzymatic effect Effects 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
239000002198 insoluble material Substances 0.000 description 4
230000003993 interaction Effects 0.000 description 4
239000012669 liquid formulation Substances 0.000 description 4
239000000594 mannitol Substances 0.000 description 4
235000010355 mannitol Nutrition 0.000 description 4
241000700198 Cavia Species 0.000 description 3
108010041986 DNA Vaccines Proteins 0.000 description 3
229940021995 DNA vaccine Drugs 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
239000011543 agarose gel Substances 0.000 description 3
238000013019 agitation Methods 0.000 description 3
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
239000008346 aqueous phase Substances 0.000 description 3
TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
230000008859 change Effects 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
238000004090 dissolution Methods 0.000 description 3
238000001647 drug administration Methods 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
238000007667 floating Methods 0.000 description 3
239000007789 gas Substances 0.000 description 3
230000036541 health Effects 0.000 description 3
KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
239000000523 sample Substances 0.000 description 3
239000006104 solid solution Substances 0.000 description 3
239000007921 spray Substances 0.000 description 3
238000001694 spray drying Methods 0.000 description 3
230000006641 stabilisation Effects 0.000 description 3
238000011105 stabilization Methods 0.000 description 3
239000000758 substrate Substances 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
241000700159 Rattus Species 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
HWDSLHMSWAHPBA-UHFFFAOYSA-N [3,4,5-triacetyloxy-6-[3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(COC(=O)C)OC1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1 HWDSLHMSWAHPBA-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
239000012062 aqueous buffer Substances 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000000975 bioactive effect Effects 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
229960005069 calcium Drugs 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
230000006378 damage Effects 0.000 description 2
239000003599 detergent Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
238000000227 grinding Methods 0.000 description 2
238000003384 imaging method Methods 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
239000004434 industrial solvent Substances 0.000 description 2
229940090046 jet injector Drugs 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
238000002156 mixing Methods 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000002687 nonaqueous vehicle Substances 0.000 description 2
239000000615 nonconductor Substances 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
230000008520 organization Effects 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
230000035515 penetration Effects 0.000 description 2
229960004624 perflexane Drugs 0.000 description 2
ZJIJAJXFLBMLCK-UHFFFAOYSA-N perfluorohexane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F ZJIJAJXFLBMLCK-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
238000004321 preservation Methods 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
238000004062 sedimentation Methods 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
239000002195 soluble material Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
238000012360 testing method Methods 0.000 description 2
229960000814 tetanus toxoid Drugs 0.000 description 2
229910052719 titanium Inorganic materials 0.000 description 2
239000010936 titanium Substances 0.000 description 2
229960005196 titanium dioxide Drugs 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
238000002255 vaccination Methods 0.000 description 2
SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
235000017060 Arachis glabrata Nutrition 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
235000010777 Arachis hypogaea Nutrition 0.000 description 1
235000018262 Arachis monticola Nutrition 0.000 description 1
238000009007 Diagnostic Kit Methods 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
201000005505 Measles Diseases 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
206010036590 Premature baby Diseases 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
206010038848 Retinal detachment Diseases 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
235000003434 Sesamum indicum Nutrition 0.000 description 1
206010040880 Skin irritation Diseases 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
ZIJKGAXBCRWEOL-SAXBRCJISA-N Sucrose octaacetate Chemical compound CC(=O)O[C@H]1[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@@]1(COC(C)=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1 ZIJKGAXBCRWEOL-SAXBRCJISA-N 0.000 description 1
206010043376 Tetanus Diseases 0.000 description 1
208000003152 Yellow Fever Diseases 0.000 description 1
239000001344 [(2S,3S,4R,5R)-4-acetyloxy-2,5-bis(acetyloxymethyl)-2-[(2R,3R,4S,5R,6R)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxyoxolan-3-yl] acetate Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
238000007605 air drying Methods 0.000 description 1
125000003172 aldehyde group Chemical group 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000006399 behavior Effects 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
239000012867 bioactive agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000001055 blue pigment Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000011109 contamination Methods 0.000 description 1
229940039231 contrast media Drugs 0.000 description 1
239000002872 contrast media Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000003795 desorption Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
239000012502 diagnostic product Substances 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
239000007911 effervescent powder Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
238000004334 fluoridation Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000007710 freezing Methods 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000001307 helium Substances 0.000 description 1
229910052734 helium Inorganic materials 0.000 description 1
SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
239000008241 heterogeneous mixture Substances 0.000 description 1
238000007654 immersion Methods 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000036512 infertility Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000005865 ionizing radiation Effects 0.000 description 1
230000007794 irritation Effects 0.000 description 1
239000000832 lactitol Substances 0.000 description 1
VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
235000010448 lactitol Nutrition 0.000 description 1
229960003451 lactitol Drugs 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
238000002595 magnetic resonance imaging Methods 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000012768 mass vaccination Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000000155 melt Substances 0.000 description 1
244000005700 microbiome Species 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
239000003595 mist Substances 0.000 description 1
-1 monosaccharide sugar alcohols Chemical class 0.000 description 1
239000004570 mortar (masonry) Substances 0.000 description 1
229940031348 multivalent vaccine Drugs 0.000 description 1
230000003387 muscular Effects 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
235000019629 palatability Nutrition 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
235000020232 peanut Nutrition 0.000 description 1
WTWWXOGTJWMJHI-UHFFFAOYSA-N perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 description 1
229960001217 perflubron Drugs 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
239000007971 pharmaceutical suspension Substances 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
238000001782 photodegradation Methods 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
229910052939 potassium sulfate Inorganic materials 0.000 description 1
235000011151 potassium sulphates Nutrition 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000011027 product recovery Methods 0.000 description 1
239000003380 propellant Substances 0.000 description 1
ZMRUPTIKESYGQW-UHFFFAOYSA-N propranolol hydrochloride Chemical compound [H+].[Cl-].C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 ZMRUPTIKESYGQW-UHFFFAOYSA-N 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000005871 repellent Substances 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
239000013049 sediment Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000035939 shock Effects 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
230000036556 skin irritation Effects 0.000 description 1
231100000475 skin irritation Toxicity 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000007711 solidification Methods 0.000 description 1
230000008023 solidification Effects 0.000 description 1
238000007614 solvation Methods 0.000 description 1
238000000527 sonication Methods 0.000 description 1
239000012798 spherical particle Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
229940013883 sucrose octaacetate Drugs 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
229940031572 toxoid vaccine Drugs 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
238000004017 vitrification Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000011592 zinc chloride Substances 0.000 description 1
235000005074 zinc chloride Nutrition 0.000 description 1
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Dispersion Chemistry (AREA)
Dermatology (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

ES04013422T 2000-10-13 2000-10-13 Suspensiones liquidas farmaceuticas. Expired - Lifetime ES2337252T3 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US2000/028244 WO2002032402A1 (en)	2000-10-13	2000-10-13	Composition and method for stable injectable liquids

Publications (1)

Publication Number	Publication Date
ES2337252T3 true ES2337252T3 (es)	2010-04-22

Family

ID=21741883

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES04013422T Expired - Lifetime ES2337252T3 (es)	2000-10-13	2000-10-13	Suspensiones liquidas farmaceuticas.

Country Status (12)

Country	Link
EP (1)	EP1328255A1 (pl)
JP (1)	JP2004513093A (pl)
KR (1)	KR20030096224A (pl)
CN (1)	CN100339066C (pl)
AU (2)	AU1198601A (pl)
CA (2)	CA2424656C (pl)
ES (1)	ES2337252T3 (pl)
MX (1)	MXPA03003236A (pl)
NO (1)	NO20031706L (pl)
PL (1)	PL360052A1 (pl)
PT (1)	PT1452171E (pl)
WO (1)	WO2002032402A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2003301654A1 (en) *	2002-10-22	2004-05-13	Dainippon Pharmaceutical Co., Ltd.	Stabilized composition
JP2007001865A (ja) *	2003-09-16	2007-01-11	Ltt Bio-Pharma Co Ltd	脂溶性薬物封入微粒子、その製造法およびそれを含有する製剤
GB0408199D0 (en) *	2004-04-13	2004-05-19	Cambridge Biostability Ltd	Liquids containing suspended sugar glass particles
JP2007532619A (ja)	2004-04-13	2007-11-15	ケンブリッジバイオスタビリティリミテッド	懸濁したガラス粒子を含有する液体
GB2430880A (en) *	2005-10-04	2007-04-11	Cambridge Biostability Ltd	Pharmaceutical compositions stabilized in glassy particles
GB0523638D0 (en)	2005-11-21	2005-12-28	Cambridge Biostability Ltd	Pharmaceutical device for the administration of substances to patients
US8946200B2 (en)	2006-11-02	2015-02-03	Southwest Research Institute	Pharmaceutically active nanosuspensions
KR101340129B1 (ko) *	2008-01-18	2013-12-10	아사히 가세이 파마 가부시키가이샤	안정한 의약 조성물
US8404850B2 (en)	2008-03-13	2013-03-26	Southwest Research Institute	Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors
US8722706B2 (en)	2008-08-15	2014-05-13	Southwest Research Institute	Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts
US8309134B2 (en)	2008-10-03	2012-11-13	Southwest Research Institute	Modified calcium phosphate nanoparticle formation
WO2010146536A1 (en)	2009-06-18	2010-12-23	Koninklijke Philips Electronics N.V.	Suspension of particles with drug
WO2011007327A2 (en)	2009-07-16	2011-01-20	Koninklijke Philips Electronics N.V.	Suspension for therapeutic use and device for delivering said suspension
ES2362525B8 (es)	2009-10-08	2013-01-03	Azurebio, S.L.	Formulación de medicamentos en forma de agujas percutaneas penetrantes.
US9028873B2 (en)	2010-02-08	2015-05-12	Southwest Research Institute	Nanoparticles for drug delivery to the central nervous system
CN106132717B (zh)	2014-03-24	2018-09-14	精工爱普生株式会社	带打印装置和带打印系统
WO2015145353A1 (en) *	2014-03-27	2015-10-01	Novartis Ag	Spray-dried solid-in-oil-in-water dispersions for inhalation of active pharmaceutical ingredients

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GR78151B (pl) *	1982-04-05	1984-09-26	Alcon Lab Inc
US5518731A (en) *	1990-09-27	1996-05-21	Allergan, Inc.	Nonaqueous fluorinated drug delivery vehicle suspensions
WO1993018748A1 (en) *	1992-03-19	1993-09-30	Allergan, Inc.	Compositions comprising a drug delivery vehicle suspended in a nonaqueous fluorinated liquid
GB9705588D0 (en) *	1997-03-18	1997-05-07	Anglia Research Foundation	Stable particle in liquid formulations
US6190701B1 (en) *	1999-03-17	2001-02-20	Peter M. Ronai	Composition and method for stable injectable liquids

2000
- 2000-10-13 AU AU1198601A patent/AU1198601A/xx active Pending
- 2000-10-13 EP EP00973483A patent/EP1328255A1/en not_active Withdrawn
- 2000-10-13 JP JP2002535640A patent/JP2004513093A/ja not_active Withdrawn
- 2000-10-13 ES ES04013422T patent/ES2337252T3/es not_active Expired - Lifetime
- 2000-10-13 CA CA2424656A patent/CA2424656C/en not_active Expired - Lifetime
- 2000-10-13 MX MXPA03003236A patent/MXPA03003236A/es active IP Right Grant
- 2000-10-13 PL PL00360052A patent/PL360052A1/pl unknown
- 2000-10-13 AU AU2001211986A patent/AU2001211986B2/en not_active Ceased
- 2000-10-13 CA CA2689856A patent/CA2689856C/en not_active Expired - Lifetime
- 2000-10-13 KR KR10-2003-7004941A patent/KR20030096224A/ko not_active Ceased
- 2000-10-13 PT PT04013422T patent/PT1452171E/pt unknown
- 2000-10-13 CN CNB008199655A patent/CN100339066C/zh not_active Expired - Fee Related
- 2000-10-13 WO PCT/US2000/028244 patent/WO2002032402A1/en not_active Ceased
2003
- 2003-04-11 NO NO20031706A patent/NO20031706L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP1328255A1 (en)	2003-07-23
CA2689856C (en)	2013-09-24
CA2424656A1 (en)	2002-04-25
PT1452171E (pt)	2010-03-08
AU2001211986B2 (en)	2007-04-26
CN100339066C (zh)	2007-09-26
WO2002032402A1 (en)	2002-04-25
NO20031706D0 (no)	2003-04-11
CA2424656C (en)	2010-03-23
MXPA03003236A (es)	2004-12-03
KR20030096224A (ko)	2003-12-24
PL360052A1 (pl)	2004-09-06
NO20031706L (no)	2003-04-11
AU1198601A (en)	2002-04-29
CA2689856A1 (en)	2002-04-25
CN1527699A (zh)	2004-09-08
JP2004513093A (ja)	2004-04-30

Publication	Publication Date	Title
US6190701B1 (en)	2001-02-20	Composition and method for stable injectable liquids
CA2424656C (en)	2010-03-23	Composition and method for stable injectable liquids
EA001873B1 (ru)	2001-10-22	Стабильная частица в жидких композициях
AU2001211986A1 (en)	2002-07-04	Composition and method for stable injectable liquids
AU2005232441B2 (en)	2010-11-11	Liquids containing suspended glass particles
CN113825529A (zh)	2021-12-21	充气微泡
ES2656240T3 (es)	2018-02-26	Mejoras en la estabilización de materiales biológicos
US20010055610A1 (en)	2001-12-27	Medicament administration system
CN1674867A (zh)	2005-09-28	抗原组合物
KR20030077615A (ko)	2003-10-01	조절된 방출 접종을 위한 조성 및 방법
EP1592443A1 (en)	2005-11-09	Improved anthrax vaccines and delivery methods
AU2005203369B2 (en)	2007-08-16	Pharmaceutical liquid suspensions
JP4027881B2 (ja)	2007-12-26	安定注射液用の組成物および方法
EP1452171B1 (en)	2009-12-02	Pharmaceutical liquid suspensions
RU2259817C2 (ru)	2005-09-10	Композиция для доставки стабильных инъецируемых жидкостей и способ доставки
CN100594937C (zh)	2010-03-24	稳定的注射液组合物和方法
JP4382706B2 (ja)	2009-12-16	医薬液体懸濁物
KR100743442B1 (ko)	2007-07-30	약제적 액체 현탁액
NZ525026A (en)	2006-12-22	A two-component composition comprising particles of sugar glass and a biocompatible liquid perfluorocarbon
NZ538681A (en)	2008-05-30	A pharmaceutical composition comprising active biological ingredient carried by particles that form a stable suspension in a liquid indefinitely
ES2339783T3 (es)	2010-05-25	Liquidos que contienen particulas vitreas suspendidas.
EP2931256B1 (en)	2016-08-31	An emulsion containing a non-live medicinal substance
ES2360698T3 (es)	2011-06-08	Vacunas mejoradas contra el antrax y procedimientos de administración.
RU2003113537A (ru)	2004-09-20	Композиция для доставки стабильных инъецируемых жидкостей и способ доставки
WO2012152707A1 (en)	2012-11-15	Microemulsions